Apellis Pharmaceuticals Inc (APLS)

$38.07

-1.66

(-4.18%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Apellis Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 9 quarters, 14.38M → 172.32M (in $), with an average increase of 24.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -140.23M → -66.42M (in $), with an average increase of 45.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 77.4% return, outperforming this stock by 133.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.6% return, outperforming this stock by 285.9%

Performance

  • $38.00
    $39.64
    $38.07
    downward going graph

    0.2%

    Downside

    Day's Volatility :4.14%

    Upside

    3.95%

    downward going graph
  • $19.83
    $92.61
    $38.07
    downward going graph

    47.91%

    Downside

    52 Weeks Volatility :78.59%

    Upside

    58.89%

    downward going graph

Returns

PeriodApellis Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-31.27%
0.9%
0.0%
6 Months
-34.04%
8.7%
0.0%
1 Year
-56.06%
10.9%
0.0%
3 Years
-40.25%
17.4%
-23.0%

Highlights

Market Capitalization
4.6B
Book Value
$2.2
Earnings Per Share (EPS)
-3.43
Wall Street Target Price
77.44
Profit Margin
-79.62%
Operating Margin TTM
-36.03%
Return On Assets TTM
-27.9%
Return On Equity TTM
-122.94%
Revenue TTM
524.1M
Revenue Per Share TTM
4.33
Quarterly Revenue Growth YOY
284.3%
Gross Profit TTM
69.8M
EBITDA
-402.3M
Diluted Eps TTM
-3.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.05
EPS Estimate Next Year
1.1
EPS Estimate Current Quarter
-0.52
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Apellis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
18
Hold
4
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 103.41%

Current $38.07
Target $77.44

Technicals Summary

Sell

Neutral

Buy

Apellis Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
-12.68%
-34.04%
-56.06%
-40.25%
65.09%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
NA
NA
NA
-1.05
-1.23
-0.28
NA
2.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Buy
$4.6B
65.09%
NA
-79.62%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Wellington Management Company LLP

    12.41%
  • EcoR1 Capital, LLC

    9.36%
  • venBio Select Advisor LLC

    9.16%
  • Vanguard Group Inc

    7.83%
  • BlackRock Inc

    4.53%
  • T. Rowe Price Investment Management,Inc.

    3.79%

Corporate Announcements

  • Apellis Pharmaceuticals Inc Earnings

    Apellis Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Organization
Apellis Pharmaceuticals Inc
Employees
702
CEO
Dr. Cedric Francois M.D., Ph.D.
Industry
Distribution Services

FAQs